Transplantační medicína

In this panel, Dr. Stephen Gitelman facilitated the discussion with Prof Loredana Marcovecchio, Prof Holly O’Donnell, and Prof Jacques Beltrand. The speakers discussed the benefits of early detection of T1D in young people and how insights from screening initiatives can inform global programs, strategies for navigating conversations with individuals considering screening, and the importance of beta-cell preservation in the context of current and emerging therapeutic approaches.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform. 
  

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.

Tıpta yaşanan gelişmeler sonucunda artık yağ dokusu veya herhangi bir yerden alınan kök hücrelerinden insülin salgılayan hücre oluşturulup büyütülebiliyor. Bu da diyabet yönetiminde kök hücre dönemini beraberinde getiriyor.

Lavt blodpladetal er ét aspekt af ITP, men når vi ser det fra en anden vinkel, ser vi de mange dimensioner af ITP. ITP er en tilstand med kompleks immunologisk dysregulering, der reducerer blodpladetallet – hvilket forårsager blødning, blå mærker, træthed og andre helbredsrelaterede livskvalitetsproblemer (HRQoL) – mens det øger inflammation og risikoen for tromboemboliske hændelser (TE).^1-5

Patienter rapporterede betydelige livskvalitets (QoL) udfordringer relateret til deres sygdom¹

For ITP-patienter er flere skalaer tilgængelige til at måle og spore træthed og dens indvirkning på livskvaliteten. Disse værktøjer kan hjælpe patienter og sundhedspersonale med at vurdere symptomer og justere ITP-behandlingen derefter.^1-4